NervGen Pharma Corp.: NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

Completed NVG-291 dosing of subjects in Phase 1 clinical trialPhase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury planned to start in Q3 2023NVG-291 has been demonstrated in preclinical

Related Keywords

Vancouver ,British Columbia ,Canada ,United Kingdom ,United States ,British ,Canadian ,Dennis Riedl ,Nancy Thompson ,Huitt Tracey ,Linkedin ,British Columbia Newsfile Corp ,Nervgen Pharma Corp ,Short Form Base Shelf Prospectus ,Company Annual Information Form ,Corporate Communications ,Facebook ,Regulation Services Provider ,Venture Exchange ,Gen Pharma ,Executive Chairman ,Daniel Mikol ,Chief Medical Officer ,Vorticom Public ,Annual Information Form ,Management Discussion ,Nervgen ,Dharma ,Orp ,Nnounces ,Completion ,Closing ,Subjects ,Hase ,Linical ,Trial ,Roprietary ,Drug ,Candidate ,